Prior, synchronous and secondary malignancies in women with ovarian cancer

Kehoe, Sean; Powell, Jean

doi:10.1016/s0020-7292(00)00357-x

Cited by 6 publications

(7 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have focused on the issue of SPM after ovarian cancer. 5 – 9 , 11 – 21 Most of these studies demonstrated an increased risk of SPM, 5 – 8 , 12 , 14 , 15 , 17 , 18 , 20 but others did not. 9 , 11 , 13 Bergfeldt et al 9 proposed that findings of increased occurrence of secondary primary cancer in patients with ovarian cancer have been biased by misclassification.…”

Section: Discussionmentioning

confidence: 99%

Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan

Hung

Liu

et al. 2015

Medicine

View full text Add to dashboard Cite

To evaluate the incidence of secondary primary malignancy (SPM) in patients with ovarian cancer using a nationwide retrospective population-based dataset.Patients newly diagnosed with ovarian cancer between 1997 and 2010 were identified using Taiwan's National Health Insurance database. Patients with antecedent malignancies were excluded. Standardized incidence ratios (SIRs) for SPM were calculated and compared with the cancer incidence in the general population. Risk factors for cancer development were analyzed using Cox proportional hazard models. Effects of surgery, chemotherapy, and radiotherapy after ovarian cancer diagnosis were regarded as time-dependent variables to prevent immortal time bias.During the 14-year study period (follow-up of 56,214 person-years), 707 cancers developed in 12,127 patients with ovarian cancer. The SIR for all cancers was 2.78 (95% confidence interval 2.58–3.00). SIRs for follow-up periods of >5, 1–5, and <1 year were 1.87, 2.04, and 6.40, respectively. After the exclusion of SPM occurring within 1 year of ovarian cancer diagnosis, SIRs were significantly higher for cancers of the colon, rectum, and anus (2.14); lung and mediastinum (1.58); breast (1.68); cervix (1.65); uterus (7.96); bladder (3.17), and thyroid (2.23); as well as for leukemia (3.98) and others (3.83). Multivariate analysis showed that age ≥ 50 years was a significant SPM risk factor (hazard ratio [HR] 1.60). Different treatments for ovarian cancer, including radiotherapy (HR 2.07) and chemotherapy (HR 1.27), had different impacts on SPM risk.Patients with ovarian cancer are at increased risk of SPM development. Age ≥ 50 years, radiotherapy, and chemotherapy are independent risk factors. Close surveillance of patients at high risk should be considered for the early detection of SPM.

show abstract

Section: Discussionmentioning

confidence: 99%

Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan

Hung

Liu

et al. 2015

Medicine

View full text Add to dashboard Cite

show abstract

“…5 For most sites, our findings are moderately in accordance with the results from literature. [2][3][4][5][6][7][11][12][13] Our results show that from 5366 patients diagnosed with a malignant primary epithelial ovarian tumor, 142 cases also manifested a concurrent endometrial malignancy (2.6%). Sheu et al report six cases from 421 ovarian cancer patients, who were also diagnosed with a synchronously endometrial cancer.…”

Section: Discussionmentioning

confidence: 99%

Increased risk of concurrent primary malignancies in patients diagnosed with a primary malignant epithelial ovarian tumor

et al. 2007

View full text Add to dashboard Cite

Ovarian cancer and second malignant neoplasms are found to occur rather frequently in the same patient. From a clinical perspective, it is important to have quantitative information on concurrent malignancies in the same year of diagnosis of the epithelial ovarian cancer. In this population-based study, we used data from the Netherlands Nationwide Network for Registry of histo-and cytopathology (PALGA) and the Netherlands Cancer Registry (NCR). Data of the ovarian cancer as well as data on previous or later cancers were obtained. Agespecific cancer rates from the NCR were used to calculate expected numbers of cancer. Between 1987 and 1993, histopathology reports were identified of 4577 patients with primary epithelial malignant or primary borderline malignant ovarian cancers and its longitudinal data. As the database may lack detailed information on histopathology, a recent sample of 789 patients diagnosed with ovarian cancer in 1996-2003 was comprehensively studied as well. In the eventual data analysis of 5366 patients, 244 cases (4.5%) of concurrent primary malignancy were reported in the same year that the malignant epithelial ovarian tumor had been diagnosed against 51 expected. The observed vs expected ratio was 4.8 and the 95% confidence interval (CI) (4.3-5.5). For cancer of the uterus/endometrium the observed vs expected ratio was 62.3 (95% CI 52.5-73.5). For skin, breast, colorectal, urinary bladder, renal and cervical cancer the ratio was also larger than unity. The elevated risk of concurrent cancer may lead to clinical screening protocols. The findings on endometrial cancer may prompt research on common etiologies and biomarkers.

show abstract

“…During the last years, a number of population-based studies focusing on second primary malignancies after an ovarian cancer have been reported [3][4][5][6][7][8]. All of them concluded that as the life expectancy of ovarian cancer patients has been extended over the last two decades because of improved therapeutic modalities, second primary tumors are being diagnosed more frequently.…”

Section: Discussionmentioning

confidence: 99%

“…Esophageal carcinoma was reported in only 5 of 1296 second primary malignancies; however, whether it was squamous cell carcinoma or adenocarcinoma was not defined. Moreover, in another three studies, from the National Cancer Institute of Canada, the Cancer Registry of the Canton of Vaud, and the Birmingham study, among a total of 1859 women with ovarian cancer, 194 second primary malignancies were diagnosed and only 1 proved to be an esophageal carcinoma [3,5,8].…”

Section: Discussionmentioning

confidence: 99%